aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To Efzofitimod
-SEC Filing
Share
Why It Matters
aTyr Pharma and Kyorin ended their partnership, which means aTyr gets back full control of a medicine called efzofitimod starting next year. When companies regain control of their own medicines, watch to see if they have enough money and team to finish the work themselves.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.